Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 21

1.

Reduced T-cell Numbers and Elevated Levels of Immunomodulatory Cytokines in Metastatic Prostate Cancer Patients De Novo Resistant to Abiraterone and/or Enzalutamide Therapy.

Pal SK, Moreira D, Won H, White SW, Duttagupta P, Lucia M, Jones J, Hsu J, Kortylewski M.

Int J Mol Sci. 2019 Apr 13;20(8). pii: E1831. doi: 10.3390/ijms20081831.

2.

Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study.

Martínez Chanzá N, Xie W, Asim Bilen M, Dzimitrowicz H, Burkart J, Geynisman DM, Balakrishnan A, Bowman IA, Jain R, Stadler W, Zakharia Y, Narayan V, Beuselinck B, McKay RR, Tripathi A, Pachynski R, Hahn AW, Hsu J, Shah SA, Lam ET, Rose TL, Mega AE, Vogelzang N, Harrison MR, Mortazavi A, Plimack ER, Vaishampayan U, Hammers H, George S, Haas N, Agarwal N, Pal SK, Srinivas S, Carneiro BA, Heng DYC, Bosse D, Choueiri TK, Harshman LC.

Lancet Oncol. 2019 Apr;20(4):581-590. doi: 10.1016/S1470-2045(18)30907-0. Epub 2019 Feb 28.

PMID:
30827746
3.

Adjuvant treatment in renal cell carcinoma.

Dizman N, Adashek JJ, Hsu J, Bergerot PG, Bergerot CD, Pal SK.

Clin Adv Hematol Oncol. 2018 Aug;16(8):555-563. Review.

PMID:
30148828
4.

Biopsychosocial distress and clinical outcome in metastatic renal cell carcinoma.

Bergerot CD, Clark KL, Ashing KT, Bergerot PG, Obenchain R, Dizman N, Hsu J, Philip E, Loscalzo M, Pal SK.

Palliat Support Care. 2018 Jun 18:1-3. doi: 10.1017/S1478951518000342. [Epub ahead of print]

PMID:
29911518
5.

The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma.

McKay RR, Bossé D, Xie W, Wankowicz SAM, Flaifel A, Brandao R, Lalani AA, Martini DJ, Wei XX, Braun DA, Van Allen E, Castellano D, De Velasco G, Wells JC, Heng DY, Fay AP, Schutz FA, Hsu J, Pal SK, Lee JL, Hsieh JJ, Harshman LC, Signoretti S, Motzer RJ, Feldman D, Choueiri TK.

Cancer Immunol Res. 2018 Jul;6(7):758-765. doi: 10.1158/2326-6066.CIR-17-0475. Epub 2018 May 10.

PMID:
29748390
6.

ATM/RB1 mutations predict shorter overall survival in urothelial cancer.

Yin M, Grivas P, Emamekhoo H, Mendiratta P, Ali S, Hsu J, Vasekar M, Drabick JJ, Pal S, Joshi M.

Oncotarget. 2018 Mar 30;9(24):16891-16898. doi: 10.18632/oncotarget.24738. eCollection 2018 Mar 30.

7.

Aspirin use and long-term rates of sepsis: A population-based cohort study.

Hsu J, Donnelly JP, Chaudhary NS, Moore JX, Safford MM, Kim J, Wang HE.

PLoS One. 2018 Apr 18;13(4):e0194829. doi: 10.1371/journal.pone.0194829. eCollection 2018.

8.

National characteristics of Emergency Department visits by patients with cancer in the United States.

Hsu J, Donnelly JP, Moore JX, Meneses K, Williams G, Wang HE.

Am J Emerg Med. 2018 Nov;36(11):2038-2043. doi: 10.1016/j.ajem.2018.03.025. Epub 2018 Mar 13.

PMID:
29573899
9.

Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma.

Koshkin VS, Barata PC, Zhang T, George DJ, Atkins MB, Kelly WJ, Vogelzang NJ, Pal SK, Hsu J, Appleman LJ, Ornstein MC, Gilligan T, Grivas P, Garcia JA, Rini BI.

J Immunother Cancer. 2018 Jan 29;6(1):9. doi: 10.1186/s40425-018-0319-9.

10.

Synaptophysin expression on circulating tumor cells in patients with castration resistant prostate cancer undergoing treatment with abiraterone acetate or enzalutamide.

Pal SK, He M, Chen L, Yang L, Pillai R, Twardowski P, Hsu J, Kortylewski M, Jones JO.

Urol Oncol. 2018 Apr;36(4):162.e1-162.e6. doi: 10.1016/j.urolonc.2017.12.006. Epub 2017 Dec 27.

11.

Association of Circulating Tumor DNA (ctDNA) Detection in Metastatic Renal Cell Carcinoma (mRCC) with Tumor Burden.

Maia MC, Bergerot PG, Dizman N, Hsu J, Jones J, Lanman RB, Banks KC, Pal SK.

Kidney Cancer. 2017 Jul 26;1(1):65-70. doi: 10.3233/KCA-170007.

12.

Vitamin K epoxide reductase expression and prostate cancer risk.

Tew BY, Pal SK, He M, Tong T, Wu H, Hsu J, Liu X, Neuhausen SL, Jones JO.

Urol Oncol. 2017 Mar;35(3):112.e13-112.e18. doi: 10.1016/j.urolonc.2016.10.020. Epub 2016 Nov 23.

PMID:
27889279
13.

Relationship of smoking status to genomic profile, chemotherapy response and clinical outcome in patients with advanced urothelial carcinoma.

Joshi M, Vasekar M, Grivas P, Emamekhoo H, Hsu J, Miller VA, Stephens PJ, Ali SM, Ross JS, Zhu J, Warrick J, Drabick JJ, Holder SL, Kaag M, Li M, Pal SK.

Oncotarget. 2016 Aug 9;7(32):52442-52449. doi: 10.18632/oncotarget.9449.

14.

Stool Bacteriomic Profiling in Patients with Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor-Tyrosine Kinase Inhibitors.

Pal SK, Li SM, Wu X, Qin H, Kortylewski M, Hsu J, Carmichael C, Frankel P.

Clin Cancer Res. 2015 Dec 1;21(23):5286-93. doi: 10.1158/1078-0432.CCR-15-0724. Epub 2015 Jul 7.

15.

Endothelial cell FGF signaling is required for injury response but not for vascular homeostasis.

Oladipupo SS, Smith C, Santeford A, Park C, Sene A, Wiley LA, Osei-Owusu P, Hsu J, Zapata N, Liu F, Nakamura R, Lavine KJ, Blumer KJ, Choi K, Apte RS, Ornitz DM.

Proc Natl Acad Sci U S A. 2014 Sep 16;111(37):13379-84. doi: 10.1073/pnas.1324235111. Epub 2014 Aug 19.

16.

The multicopper ferroxidase hephaestin enhances intestinal iron absorption in mice.

Fuqua BK, Lu Y, Darshan D, Frazer DM, Wilkins SJ, Wolkow N, Bell AG, Hsu J, Yu CC, Chen H, Dunaief JL, Anderson GJ, Vulpe CD.

PLoS One. 2014 Jun 4;9(6):e98792. doi: 10.1371/journal.pone.0098792. eCollection 2014.

17.

Impact of age on treatment trends and clinical outcome in patients with metastatic renal cell carcinoma.

Pal SK, Hsu J, Hsu S, Hu J, Bergerot P, Carmichael C, Saikia J, Liu X, Lau C, Twardowski P, Figlin RA, Yuh BF.

J Geriatr Oncol. 2013 Apr;4(2):128-33.

18.

Preoperative therapy for localized prostate cancer: a comprehensive overview.

Hu J, Hsu J, Bergerot PG, Yuh BE, Stein CA, Pal SK.

Maturitas. 2013 Jan;74(1):3-9. doi: 10.1016/j.maturitas.2012.10.012. Epub 2012 Nov 14. Review.

19.

Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell tumor: clinical outcome and quality of life in long-term survivors.

Pal SK, Yamzon J, Sun V, Carmichael C, Saikia J, Ferrell B, Frankel P, Hsu J, Twardowski P, Stein CA, Margolin K.

Clin Genitourin Cancer. 2013 Jun;11(2):121-7. doi: 10.1016/j.clgc.2012.09.007. Epub 2012 Oct 11.

20.

Quality of life in patients with metastatic renal cell carcinoma: assessment of long-term survivors.

Carmichael C, Yuh BE, Sun V, Lau C, Hsu J, Saikia J, Liu X, Wilson T, Ferrell B, Pal SK.

Clin Genitourin Cancer. 2013 Jun;11(2):149-54. doi: 10.1016/j.clgc.2012.09.006. Epub 2012 Oct 9.

Supplemental Content

Loading ...
Support Center